Summary
Significant changes in the Swedish reimbursement system for drugs were introduced on January 1,1993. A reference price system was introduced and price control became the responsibility of the National Social Insurance Board (NSIB). If a drug is to be reimbursed when prescribed, the price must be approved by the NSIB. The prices for drugs included in the reference price system do not have to be approved by the NSIB, as the reimbursement level is fixed at 10% above the price of the cheapest generic.
Several pricing strategies were developed by pharmaceutical companies after these changes. For original products within the reference price system, the price, with few exceptions, was dropped to the reimbursement price. Total sales for compounds with reference prices decreased in value and the market share for generic products increased. Some products and package sizes, mainly with regard to hospital drugs, were withdrawn from reimbursement and the prices increased. The total sales of drugs for human use increased by about 6.5% during the first 6 months of 1993 when compared with the same period the previous year. There was a slight decrease (1.6%) in total expenditure for the reimbursement scheme (NSIB), but an increase of 14% for patient copayments during the first 3 months compared with the same period the year before.
Cost containment has become a major priority for all publically financed programmes. However, the changes in the Swedish drug reimbursement system have not produced significant savings in public expenditure and further changes may be expected.
Similar content being viewed by others
References
Apoteksbolaget (National Corporation of Swedish Pharmacies) 1993
Jönsson B. The pharmaceutical market. In Bourdet Y (Ed.) Internationalization, market power and consumer welfare, Routledge, New York, 1991
Gerdtham U. Läkemedelsförsörjningen i Sverige, Center for medical technology assessment, Discussion paper: 2, Linköping University, 1989 4. RFV (National Social Insurance Board), 1993 5. Läkartidningen. p. 657 (Editorial’ Läkemedelskaos?) and pp. 667-70, 1993 6. Fakta 93. Läkemedelsmarknaden och hälso- och sjukvården (Pharmaceutical market and health care), LIF/RUFI, 1993 7. Läkemedelsstatistik AB, Swedish drug market (SDM)
RFV (National Social Insurance Board), 1993
Läkartidningen. p. 657 (Editorial ‘Läkemedelskaos?) and pp. 667–70, 1993
Fakta 93. Läkemedelsmarknaden och hälso- och sjukvården (Pharmaceutical market and health care), L1F/RUFI, 1993
Läkemedelsstatistik AB, Swedish drug market (SDM)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jönsson, B. Pricing and Reimbursement of Pharmaceuticals in Sweden. Pharmacoeconomics 6 (Suppl 1), 51–60 (1994). https://doi.org/10.2165/00019053-199400061-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199400061-00013